Results
This paper reports the findings from the initial phase of the study up to Day 28. The immunogenicity results from the PP population are presented. The disposition of the pregnant women meeting the protocol requirements is shown in Trial profile (pregnant women).To assess the primary objective of the present study, we added the PP population from women of childbearing age (250 women consisting of 50 in each vaccine group) to the PP population of pregnant women (394 pregnant women). Hence, the pooled population included 644 participants in total (Pooled population of pregnant women and non-pregnant women of childbearing age.Demographic characteristics (age, ethnicity, height, and body weight) at baseline were similar for participants in all vaccine groups (Baseline demographic characteristics.